 |
|
|
|
|
|
|
| The following information (Health Effects, Handling/Disposal, and Ingredients) is taken from the product label and/or the Material Safety Data Sheet (MSDS) prepared by the manufacturer. The National Library of Medicine does not test products nor does it evaluate information from the product label or the MSDS.
|
 |
|
|
|
Health Effects
|
|
CAUSES EYE IRRITATION
- HARMFUL IF SWALLOWED
- DO NOT GET IN EYES, ON SKIN, OR ON CLOTHING
- EXTREMELY FLAMMABLE
- CONTENTS UNDER PRESSURE
- KEEP OUT OF REACH OF CHILDREN
|
From MSDS
POTENTIAL HEALTH EFFECTS
EYES: This substance is slightly irritating to the eyes. Eye contact may include discomfort, tearing, swelling, redness, and blurred vision.
SKIN: This substance is not expected to cause prolonged or significant skin irritation. If absorbed through the skin, this substance is considered practically non-toxic to internal organs. This product is not expected to cause allergic skin reaction.
INGESTION: Ingestion may cause irritation of the digestive tract which may include nausea, vomiting, and diarrhea. If swallowed, this substance is considered practically non-toxic to internal organs.
INHALATION: Overexposure to spray mist may result in minor irritation of the upper respiratory tract. See Toxicology Information section (11) for more information.
COMMENTS HEALTH: Depending upon the extent and degree of overexposure to the product, signs and symptoms of cholinesterase inhibition can result following either ingestion, skin contact or inhalation routes of exposure. Signs and symptoms of cholinesterase inhibition can result from either acute (one time), subchronic (repeated short-term) and chronic (daily life-time) overexposure to the product.
Signs and symptoms of cholinesterase inhibition usually occur within 12 hours following overexposure. These effects may include, but may not be limited to, headache, dizziness, weakness, nausea, vomiting, diarrhea, constriction of the pupil of the eye, blurred or dark vision, excessive salivation or nasal discharge, profuse sweating and abdominal cramps. Incontinence, unconsciousness, convulsions and breathing difficulties are indicative of severe poisoning. In untreated severe poisoning, death is due to respiratory failure or cardiac arrest.
|
From MSDS
Depending upon the extent and degree of overexposure to the product, signs and symptoms of cholinesterase inhibition can result following either ingestion, skin contact or inhalation routes of exposure. Signs and symptoms of cholinesterase inhibition can result from either acute (one time), subchronic (repeated short-term) and chronic (daily life-time) overexposure to the product.
Signs and symptoms of cholinesterase inhibition usually occur within 12 hours following overexposure. These effects may include, but may not be limited to, headache, dizziness, weakness, nausea, vomiting, diarrhea, constriction of the pupil of the eye, blurred or dark vision, excessive salivation or nasal discharge, profuse sweating and abdominal cramps. Incontinence, unconsciousness, convulsions and breathing difficulties are indicative of severe poisoning. In untreated severe poisoning, death is due to respiratory failure or cardiac arrest.
CHRONIC: Results of the rat chronic acephate feeding study indicate that the no observed effect level (NOEL) was 5 parts per million (ppm) or (0.25 mg/kg/dy). The NOEL's for triforine in the rat chronic study and the dog 2-year feeding study were 625 and 100 ppm (31 and 2.5 mg/kg/dy), respectively.
The dog 2-year acephate feeding study NOEL for cholinesterase inhibition was 30 ppm (0.75 mg/kg/dy). The effect level for cholinesterase inhibition occurred at the high dose of 200 ppm (5 mg/kg/dy).
NEUROTOXICITY: Based on the results of the chicken neurotoxicity studies, acephate has not demonstrated potential to cause delayed neuropathy. Triforine has not been associated with neuro-histopathological changes.
TERATOGENICITY: Neither acephate or triforine have been demonstrated to cause birth defects.
REPRODUCTIVE TOXIN: When male and female rats were fed acephate continuously for two generations through weaning of the third generation, animals in the mid and high-dose groups demonstrated compound-related effects on reproductive performance. The low-dose was considered the no-effect-level. There was no evidence of adverse reproductive effects in the triforine rat 3 generation studies.
MUTAGENICITY: Acephate has demonstrated weak mutagenic potential in microbes or cultured cells, while results of in vivo studies indicate that it does not cause mutation in whole animals. Triforine is not considered to be a mutagen in either in vitro or in vivo studies.
|
From MSDS
CARCINOGENICITY COMMENTS: EPA has classed acephate in category C as a possible human carcinogen based on the liver tumor findings in the mouse lifetime feeding study. Liver pathology was observed at dose levels of 250 and 1000 ppm (37.5 and 150 mg/kg/dy), while an increased incidence of liver cancer was noted in the high dose (150 mg/kg/dy) female mice only. Acephate has not demonstrated any evidence of carcinogenic potential in any other species.
Results of a mouse lifetime Triforine feeding study indicated that there was an increased incidence of liver and lung tumors. There was no significant increase in tumors in the rat chronic study (NOEL = 626 ppm or 31.3 mg/kg/dy).
|
From MSDS
EYES: Flush eyes immediately with fresh water for at least 15 minutes while holding the eyelids open. Remove contact lenses if worn. Call a physician.
SKIN: No first aid procedures are required. As a precaution, wash skin thoroughly with soap and water. Remove and wash contaminated clothing.
INGESTION: If a large amount of the liquid is swallowed, give a large quantity of water to drink, make person vomit and call a doctor. Never give anything by mouth to an unconscious person.
INHALATION: If respiratory discomfort or irritation occurs, move the person to fresh air. See a doctor if discomfort or irritation continues.
NOTES TO PHYSICIAN: This material contains a cholinesterase inhibitor. Measurement of blood cholinesterase activity may be useful in monitoring exposure. If signs of cholinesterase inhibition appear, atropine sulfate is antidotal. 2-PAM (PROTOPAM) is also antidotal and may be used in conjunction with atropine but should not be used alone.
ADDITIONAL INFORMATION: Medical Information: Call day or night, 1-800-454-2333 OR 1-800-457-2022.
|
| 1 |
| 4 |
| 0 |
0 = Minimal; 1 = Slight; 2 = Moderate; 3 = Serious; 4 = Severe;
N = No information provided by manufacturer; * = Chronic Health Hazard |
| 1996-12-02 |
|
|
|
|
|
|
|
|
Handling/Disposal
|
From MSDS
GENERAL PROCEDURES: READ AND OBSERVE ALL PRECAUTIONS ON PRODUCT LABEL. Store in accordance with NFPA 30B for a Level III aerosol. DO NOT USE OR STORE near flame, sparks or hot surfaces. USE ONLY IN WELL VENTILATED AREA. CONTAINER UNDER PRESSURE. Exposure to heat or prolonged exposure to sun may cause container to burst. Do not puncture, incinerate or store above 130�F.
ECOTOXICOLOGICAL INFORMATION: This pesticide is highly toxic to fish. Do not apply directly to water or wetlands (swamps, bogs, marches and potholes). Drift and runoff from treated sites may be hazardous to dish in adjacent waters.
|
From MSDS
The Solaris Group is committed to responsible environmental practices and recommends that all of the product be used up, carefully following all label directions and precautions.
If necessary to dispose of partially filled product container, then securely wrap it in several layers of newspaper and discard in trash.
EMPTY CONTAINER: Do not reuse empty container. Discard container in trash.
|
|
|
|
|
|
|
|
|
Ingredients from MSDS/Label
|
|
|
|
|
|
|
|
|
|
Home
| Brands | Manufacturers
| Ingredients | Health
Effects
|
|
